Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.

Alimentary pharmacology & therapeutics - 1 Jun 2001

Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T

Abstract excerpt

BACKGROUND: S-mephenytoin 4'-hydroxylase (CYP2C19) catalyses the metabolism of rabeprazole to some extent. Based on the metabolic and pharmacokinetic differences among other proton pump inhibitors such as omeprazole, lansoprazole and pantoprazole, rabeprazole appears to be the least affected proton pump inhibitor by the CYP2C19-related genetic polymorphism. AIM: To determine whether the pharmacodynamic effects of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anti-Ulcer Agents

Share to Benzimidazoles

Share to Cross-Over Studies

Share to Gastrins

Share to Omeprazole

Share to Rabeprazole

Source

Identifiers

PMID: 11380317
DOI: 10.1046/j.1365-2036.2001.00980.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.PMID 11380317Read ↗

Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.Semantic proximity Read ↗

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.Semantic proximity Read ↗

CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.Semantic proximity Read ↗

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.Semantic proximity Read ↗

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.Semantic proximity Read ↗

CYP2C19 genotype and the PPIs--focus on rabeprazole.Semantic proximity Read ↗

Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.Semantic proximity Read ↗

Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers.Semantic proximity Read ↗

Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.Semantic proximity Read ↗

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.Semantic proximity Read ↗

Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.Semantic proximity Read ↗

Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.